Trials / Recruiting
RecruitingNCT06150781
Aimovig Pregnancy Exposure Registry
GENESIS: AIMOVIG® Pregnancy Exposure Registry
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,842 (estimated)
- Sponsor
- Amgen · Industry
- Sex
- Female
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed to erenumeb-aooe.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | erenumab-aooe | Dose and treatment duration will be advised by the HCP |
Timeline
- Start date
- 2021-01-27
- Primary completion
- 2027-10-28
- Completion
- 2027-10-28
- First posted
- 2023-11-29
- Last updated
- 2025-11-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06150781. Inclusion in this directory is not an endorsement.